BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21400189)

  • 1. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.
    Atkinson MA; White CT
    Pediatr Nephrol; 2012 Jan; 27(1):33-40. PubMed ID: 21400189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
    Coyne DW
    Kidney Int; 2011 Aug; 80(3):240-4. PubMed ID: 21677632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin for clinicians.
    Young B; Zaritsky J
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.
    Sun CC; Vaja V; Chen S; Theurl I; Stepanek A; Brown DE; Cappellini MD; Weiss G; Hong CC; Lin HY; Babitt JL
    Nephrol Dial Transplant; 2013 Jul; 28(7):1733-43. PubMed ID: 23345622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
    Nakanishi T; Kuragano T; Kaibe S; Nagasawa Y; Hasuike Y
    Clin Exp Nephrol; 2012 Dec; 16(6):819-26. PubMed ID: 23053592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
    Ueda N; Takasawa K
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin is a potential regulator of iron status in chronic kidney disease.
    Tsuchiya K; Nitta K
    Ther Apher Dial; 2013 Feb; 17(1):1-8. PubMed ID: 23379486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
    van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
    PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
    Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum hepcidin-25 in comparison to biochemical markers and hematological indices for the differentiation of iron-restricted erythropoiesis.
    Thomas C; Kobold U; Thomas L
    Clin Chem Lab Med; 2011 Feb; 49(2):207-13. PubMed ID: 21143009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron supplementation to treat anemia in patients with chronic kidney disease.
    Besarab A; Coyne DW
    Nat Rev Nephrol; 2010 Dec; 6(12):699-710. PubMed ID: 20956992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.
    Babitt JL; Lin HY
    Am J Kidney Dis; 2010 Apr; 55(4):726-41. PubMed ID: 20189278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepcidin as a biomarker for the diagnosis of iron metabolism disorders: a review.
    Vermeulen E; Vermeersch P
    Acta Clin Belg; 2012; 67(3):190-7. PubMed ID: 22897067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
    Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
    Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
    Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
    Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
    Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in anemias related to chronic conditions.
    Guidi GC; Lechi Santonastaso C
    Clin Chem Lab Med; 2010 Sep; 48(9):1217-26. PubMed ID: 20618092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia in chronic kidney disease: new advances.
    Patel TV; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):347-57. PubMed ID: 20630409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats.
    Theurl M; Nairz M; Schroll A; Sonnweber T; Asshoff M; Haschka D; Seifert M; Willenbacher W; Wilflingseder D; Posch W; Murphy AT; Witcher DR; Theurl I; Weiss G
    Haematologica; 2014 Sep; 99(9):1516-24. PubMed ID: 24895335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
    Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.